Timothy Wyant

1.6k total citations
38 papers, 1.3k citations indexed

About

Timothy Wyant is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Timothy Wyant has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Timothy Wyant's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (7 papers). Timothy Wyant is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (7 papers). Timothy Wyant collaborates with scholars based in United States, Australia and Canada. Timothy Wyant's co-authors include Marcelo B. Sztein, Michael K. Tanner, Maria Rosario, Carol O. Tacket, Myron M. Levine, Irving H. Fox, Brian G. Feagan, Lili Yang, William L. Trepicchio and A. Parikh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Timothy Wyant

35 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Wyant United States	17	515	297	269	236	221	38	1.3k
Elizabeth Jones United Kingdom	17	624 1.2×	110 0.4×	266 1.0×	94 0.4×	228 1.0×	34	1.3k
C Roudier France	15	305 0.6×	194 0.7×	105 0.4×	82 0.3×	346 1.6×	25	1.2k
Chiedzo Mpofu United Kingdom	6	137 0.3×	418 1.4×	165 0.6×	255 1.1×	88 0.4×	10	988
Diane U. Leong United States	10	907 1.8×	350 1.2×	127 0.5×	516 2.2×	72 0.3×	12	2.2k
Elodie Mohr United Kingdom	21	1.0k 1.9×	67 0.2×	155 0.6×	199 0.8×	70 0.3×	32	1.5k
Midori Kobayashi Japan	22	208 0.4×	250 0.8×	206 0.8×	1.0k 4.3×	62 0.3×	69	2.0k
Harald Peeters Belgium	20	468 0.9×	839 2.8×	175 0.7×	530 2.2×	62 0.3×	58	1.7k
Virginia Lockatell United States	19	413 0.8×	108 0.4×	173 0.6×	429 1.8×	60 0.3×	27	1.5k
Yuehua Zhou China	12	668 1.3×	120 0.4×	93 0.3×	93 0.4×	93 0.4×	22	1.1k
Samuel Lundin Sweden	22	916 1.8×	182 0.6×	103 0.4×	163 0.7×	58 0.3×	41	1.7k

Countries citing papers authored by Timothy Wyant

Since Specialization

Citations

This map shows the geographic impact of Timothy Wyant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Wyant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Wyant more than expected).

Fields of papers citing papers by Timothy Wyant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Wyant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Wyant. The network helps show where Timothy Wyant may publish in the future.

Co-authorship network of co-authors of Timothy Wyant

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Wyant. A scholar is included among the top collaborators of Timothy Wyant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Wyant. Timothy Wyant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wyant, Timothy, Drew Rasco, Andrew Haydon, et al.. (2024). 464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells. European Journal of Cancer. 211. 114971–114971.

Rasco, Drew, Meredith McKean, Andrew Haydon, et al.. (2024). Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2527–2527. 1 indexed citations

Wyant, Timothy, Sophia Frentzas, Elizabeth Ahern, et al.. (2023). Abstract C033: Preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors. Molecular Cancer Therapeutics. 22(12_Supplement). C033–C033. 1 indexed citations

Wyant, Timothy, Sharon Fischman, Guy Nimrod, et al.. (2023). Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies. 5(1). 29–39. 5 indexed citations

Wyant, Timothy, Lili Yang, & Maria Rosario. (2020). Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. The AAPS Journal. 23(1). 3–3. 19 indexed citations

Powderly, John D., Manish R. Patel, Jina Lee, et al.. (2017). CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study. Annals of Oncology. 28. v405–v406. 45 indexed citations

Danaee, Hadi, Thea Kalebic, Timothy Wyant, et al.. (2017). Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS ONE. 12(12). e0189953–e0189953. 27 indexed citations

Lazorchak, Adam S., Pottayil G. Sasikumar, Raghuveer Ramachandra, et al.. (2017). Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer. Cancer Immunology Research. 5(3_Supplement). A36–A36. 9 indexed citations

Rosario, Maria, Timothy Wyant, Timothy Leach, et al.. (2016). Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. Clinical Drug Investigation. 36(11). 913–923. 38 indexed citations

10.

Reinisch, Walter, James D. Lewis, Themistocles Dassopoulos, et al.. (2015). DOP042. Clinical response and remission with vedolizumab across a range of baseline fecal calprotectin levels in ulcerative colitis: Results from GEMINI 1. Journal of Crohn s and Colitis. 9(suppl 1). S47–S47. 2 indexed citations

11.

Bowsher, Ronald R., Mark J. Cameron, Viswanath Devanarayan, et al.. (2015). Recommendations for Adaptation and Validation of Commercial Kits for Biomarker Quantification in Drug Development. Bioanalysis. 7(2). 229–242. 19 indexed citations

12.

Rosario, Maria, Nathanael L. Dirks, Marc R. Gastonguay, et al.. (2015). Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Alimentary Pharmacology & Therapeutics. 42(2). 188–202. 202 indexed citations

13.

Estevam, Jose, Hadi Danaee, Ray Liu, et al.. (2010). Validation of a flow cytometry based G2M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition. Journal of Immunological Methods. 363(2). 135–142. 12 indexed citations

14.

Wyant, Timothy, et al.. (2008). Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist. Journal of Translational Medicine. 6(1). 76–76. 13 indexed citations

15.

Vergunst, Clarissa E., Daniëlle M. Gerlag, Lars Klareskog, et al.. (2008). Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Arthritis & Rheumatism. 58(7). 1931–1939. 178 indexed citations

16.

Salerno-Gonçalves, Rosângela, Timothy Wyant, Marcela F. Pasetti, et al.. (2003). Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with Salmonella enterica Serovar Typhi Strain CVD 908-htrA. The Journal of Immunology. 170(5). 2734–2741. 79 indexed citations

17.

Tacket, Carol O., James E. Galen, Marcelo B. Sztein, et al.. (2000). Safety and Immune Responses to Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccines Expressing Tetanus Toxin Fragment C. Clinical Immunology. 97(2). 146–153. 61 indexed citations

18.

Wyant, Timothy, Michael K. Tanner, & Marcelo B. Sztein. (1999). Potent Immunoregulatory Effects ofSalmonella typhiFlagella on Antigenic Stimulation of Human Peripheral Blood Mononuclear Cells. Infection and Immunity. 67(3). 1338–1346. 53 indexed citations

19.

Hirsch, Robert M., et al.. (1982). Investigation of trends in flooding in the Tug Fork basin of Kentucky, Virginia, and West Virginia. Antarctica A Keystone in a Changing World. 5 indexed citations

20.

Slack, James Richard, et al.. (1980). The oilspill risk analysis model of the U. S. Geological Survey. Antarctica A Keystone in a Changing World. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact